Windtree Therapeutics Inc (WINT)

$3.35

-0.15

(-4.29%)

Market is closed - opens 7 PM, 05 Jun 2024

Performance

  • $3.35
    $3.56
    $3.35
    downward going graph

    0.0%

    Downside

    Day's Volatility :5.9%

    Upside

    5.9%

    downward going graph
  • $3.35
    $35.10
    $3.35
    downward going graph

    0.0%

    Downside

    52 Weeks Volatility :90.46%

    Upside

    90.46%

    downward going graph

Returns

PeriodWindtree Therapeutics Inc
3 Months
-50.14%
6 Months
-78.52%
1 Year
-87.12%
3 Years
-99.86%

Highlights

Market Capitalization
2.1M
Book Value
$30.23
Earnings Per Share (EPS)
13.31
PE Ratio
0.27
PEG Ratio
0.0
Wall Street Target Price
3.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-33.58%
Return On Equity TTM
-53.1%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
-17.8M
EBITDA
-17.5M
Diluted Eps TTM
13.31
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.97
EPS Estimate Next Year
-0.66
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Windtree Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
3
3
3

Analyst Forecast

What analysts predicted

Downside of 10.45%

Current $3.35
Target $3.00

Technicals Summary

Sell

Neutral

Buy

Windtree Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Windtree Therapeutics Inc
Windtree Therapeutics Inc
-28.21%
-78.52%
-87.12%
-99.86%
-99.94%
Moderna, Inc.
Moderna, Inc.
21.03%
85.08%
14.68%
-28.27%
659.22%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.22%
20.54%
31.88%
92.14%
229.83%
Novo Nordisk A/s
Novo Nordisk A/s
8.85%
36.12%
71.83%
234.04%
457.53%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
16.81%
32.76%
40.6%
124.79%
171.36%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Windtree Therapeutics Inc
Windtree Therapeutics Inc
0.27
0.27
0.0
-0.97
-0.53
-0.34
NA
30.23
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.89
28.89
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.97
46.97
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.59
29.59
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Windtree Therapeutics Inc
Windtree Therapeutics Inc
Sell
$2.1M
-99.94%
0.27
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.6B
659.22%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
229.83%
28.89
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$602.6B
457.53%
46.97
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
171.36%
29.59
39.46%

Institutional Holdings

  • Vanguard Group Inc

    0.45%
  • Virtu Financial LLC

    0.42%
  • Geode Capital Management, LLC

    0.15%
  • UBS Group AG

    0.01%

Company Information

windtree therapeutics, inc. is a biotechnology company focused on developing novel kl4 surfactant therapies for respiratory diseases and other potential applications. windtree’s proprietary technology platform includes a synthetic, peptide-containing surfactant (kl4 surfactant ) that is structurally similar to human pulmonary surfactant — and novel drug-delivery technologies that are being developed to enable noninvasive administration of aerosolized kl4 surfactant. windtree is focused initially on improving the management of respiratory distress syndrome (rds) in premature infants as surfactant therapy has been shown to save lives in this condition. windtree believes that its proprietary technologies may make it possible, over time, to develop a pipeline of kl4 surfactant product candidates to address a variety of respiratory diseases for which there are few or no approved therapies and, in doing so, potentially deliver a lifetime of hope to patients and their families.

Organization
Windtree Therapeutics Inc
Employees
0
CEO
Mr. Craig E. Fraser
Industry
Biotechnology

FAQs